Yield10 Bioscience Announces Closing of $4.0 Million Public Offering, Including Exercise of the Over-Allotment Option, and Concurrent $1.7 Million Private Placement

WOBURN, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share.  In addition, Maxim Group LLC has exercised its over-allotment option to purchase 116,835 shares of common stock, at the public offering price less underwriting discounts. Gross proceeds before deducting underwriting discounts and commissions and other offering expenses are approximately $4.0 million, inclusive of the over-allotment. Concurrent with the public offering, investors affiliated with existing investor Jack W. Schuler purchased 396,450 shares of Yield10’s common stock pursuant to a securities purchase agreement at the same price per share as in the public offering, in a separate private placement transaction.  The gross proceeds from the private placement were approximately $1.7 million. All shares in the public offering and private placement were sold by Yield10.
Maxim Group LLC acted as the sole book-running manager for the public offering.The public offering was made pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on April 1, 2020 and declared effective on April 10, 2020.  A final prospectus supplement describing the terms of the public offering has been filed with the SEC and will form a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, or by telephone at (212) 895-3745.The shares sold in the private placement have not been and will not be registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.About Yield10 Bioscience